



JAMES L. MADARA, MD
EXECUTIVE VICE PRESIDENT, CEO

ama-assn.org
t (312) 464-5000

March 3, 2020

Jeff Francer
Interim CEO and General Counsel
Association for Accessible Medicines
601 New Jersey Ave NW, Suite 850
Washington, DC 20001

Dear Mr. Francer:

On behalf of the American Medical Association (AMA) and our physician and medical student members, I am writing to encourage the manufacturers of pharmaceutical pain care options to seek U.S. Food and Drug Administration approval for additional indications related to non-opioid pain management therapy.

This letter reflects policy adopted by the AMA House of Delegates, our policy-setting body, at its 2019 Annual Meeting. That policy called on the AMA to advocate for increased access and coverage of non-opioid treatment modalities including pharmaceutical pain care options, interventional pain management procedures, restorative therapies, behavioral therapies, physical and occupational therapy and other evidence-based therapies recommended by the patient's physician. The policy further called on the AMA to advocate for non-opioid treatment modalities being placed on the lowest cost-sharing tier for the indication of pain so that patients have increased access to evidence-based pain care as recommended by the U.S. Department of Health and Human Services Interagency Pain Care Task Force.

As representatives of individual companies that manufacture and develop pharmaceutical and other pain care options, the AMA urges you to share this letter with those organizations and encourage their support for the AMA policy noted above.

If you have any questions, please direct them to Daniel Blaney-Koen, JD, Senior Legislative Attorney, AMA Advocacy Resource Center, at daniel.blaney-koen@ama-assn.org or (312) 464-4954.

Thank you for your consideration.

Sincerely,

A handwritten signature in black ink, appearing to read "James L. Madara". The signature is written in a cursive, flowing style.

James L. Madara, MD